Programme | Toulouse Onco Week 2020

1. Scientific & B2B Programme
2. Programme
Programme
Preliminary programme up to date 30 Dec. 2019
Download preliminary detailed programme

Detailed programme & abstracts

14:00 - 15:00 - Charting mechanisms of tumor progression and therapeutic resistance *Douglas HANAHAN,* Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland
15:00 - 16:00 - Hypoxia, Metabolism, and Tumor Progression *M. Celeste SIMON,* Abramson Family Cancer Research Institute, UPenn, Philadelphia, PA, United States
16:00 - 17:00 - Multiple Myeloma: From (almost) no treatment to cure. The past 20 years story *Hervé AVET-LOISEAU,* Cancer Research Center of Toulouse (CRCT), France,

17:30 - 19:30 Ice Breaking Event (including poster sessions)

09:00 - 12:15 Session 1 : Can we really improve DNA damaging agents efficacy ?

Session 1 : Can we really improve DNA damaging agents efficacy ?

09:00 - 09:40 - Precision Medicine with DNA-targeted agents *Yves POMMIER,* Developmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, United States
09:40 - 09:55 - Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks *Olivier SORDET,* Cancer Research Center of Toulouse (CRCT), France
09:55 - 10:35 - Roles of the BRCA1/2 tumour suppressors in DNA replication and repair *Madalena TARSOUNAS,* University of Oxford, United Kingdom
10:35 - 11:05 - Coffee break - Poster session
11:05 - 11:20 - Telomere and nuclear envelope interaction to drive and maintain 3D genome organization *Laure CRABBE,* Center for Integrative Biology (CBI), Toulouse, France
11:20 - 11:35 - Chromosome folding controls the response to DNA Double Strand Breaks and translocations *Coline ARNOULD,* Center for Integrative Biology (CBI), Toulouse, France
11:35 - 12:15 - From DNA repair mechanisms to drug discovery *Sébastien BRITTON,* Institute of Pharmacology and Structural Biology (IPBS), Toulouse, France

12:15 - 13:00 Pitches

13:00 - 14:15 Lunchtime - Poster session

14:15 - 17:30 Session 2 : Targeted therapies and resistance mechanisms

Session 2 : Targeted therapies and resistance mechanisms

14:15 - 14:55 - Genomic profiling of metastatic breast cancer *Fabrice ANDRÉ,* Gustave Roussy, Villejuif, France
14:55 - 15:10 - Preventing acquired resistance to therapy by targeting tumor evolution: a new strategy to prolong lung cancer response to EGFR inhibition *Luca GRUMOLATO,* Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
15:10 - 15:50 - Targeting PI3K isoforms in pancreatic cancer: novel concepts of cooperation / competition in signalling nodes. *Julie GUILLERMET-GUIBERT,* Cancer Research Center of Toulouse (CRCT), France
15:50 - 16:20 - Coffee break - Poster session
16:20 - 16:35 - Aryl hydrocarbon Receptor transcription factor promotes “phenotype switching” during acquisition of BRAFi-resistance of melanoma. *Sébastien CORRE,* Institute Genetics & Development of Rennes (IGDR), France
16:35 - 16:50 - Targeting cancer stem cells to overcome BRAF mutated tumor resistance in CRC *Julie PANNEQUIN,* Institute of Functional Genomics (IGF), Montpellier, France
16:50 - 17:30 - Nongenetic mechanisms of tumor evolution and therapy resistance *Jean-Christophe MARINE,* VIB KU Leuven Center For Cancer Biology, Belgium

18:00 - 21:30 Public Conference (french only)

09:00 - 12:20 Session 3 : Translating oncoimmunology science into survival - With institutional support of MSD

Session 3 : Translating oncoimmunology science into survival - With institutional support of MSD

09:00 - 09:40 - Immunotherapy Approaches in Hematological Malignancies: Pushing the Envelope Towards a Cure *Nikhil C. MUNSHI,* Dana Farber Institute, Medical Oncology, Boston, MA, United States
09:40 - 09:55 - Tumor antigen-specific CD8 T cells identified by TIM-3 expression predict response to PD-1 blockade in head and neck cancer *Camille-Charlotte BALANÇA,* Cancer Research Center of Toulouse (CRCT), France
09:55 - 10:35 - New insights from the multimodal profiling of human tumors at the single cell level *Jean-Jacques FOURNIE,* Cancer Research Center of Toulouse (CRCT), France
10:35 - 11:05 - Coffee break - Poster session
11:05 - 11:20 - High endothelial venules mediate lymphocyte entry to tumor after CTLA-4 and PD-1 immune checkpoint therapy *Juliette COUDERT,* Institute of Pharmacology and Structural Biology (IPBS), Toulouse, France
11:20 - 11:35 - Polyclonal anti-tumor cell globulins induce target cell apoptosis and synergize with checkpoint blockade immunotherapy to eradicate hepatocellular carcinoma. *Bernard VANHOVE,* Xenothera, Nantes, France
11:35 - 11:50 - Neutral sphingomyelinase 2 promotes anti-melanoma immune responses and synergizes with immune checkpoint inhibitors. *Anne MONTFORT,* Cancer Research Center of Toulouse (CRCT), France
11:50 - 12:05 - Protective role of localized Ca2+ entry into melanoma cells upon rapid CTL lytic granule secretion *Liza Filali,* Cancer Research Center of Toulouse (CRCT), France
12:05 - 12:20 - LungPredict: Transcriptomics and imaging to explore the lung cancer tumor microenvironment landscape, a multidisciplinary approach to personalized medicine *Vera PANCALDI,* Cancer Research Center of Toulouse (CRCT), France

12:20 - 13:00 Pitches

13:00 - 14:15 Lunchtime - Poster session

14:15 - 17:30 Session 4 : Metabolic vulnerabilities–driven therapies

Session 4 : Metabolic vulnerabilities–driven therapies

14:15 - 14:55 - *Marina KONOPLEVA,* MD Anderson Cancer Center, Houston, TX, United States
14:55 - 15:10 - Mitochondrial respiratory complex I supports resistance to venetoclax plus cytarabine in acute myeloid leukemia *Claudie BOSC,* Cancer Research Center of Toulouse (CRCT), France
15:10 - 15:50 - Mitochondria and Cancer *Christian FREZZA,* MRC Cancer Unit, University Of Cambridge, United Kingdom
15:50 - 16:20 - Coffee break - Poster session
16:20 - 16:35 - Autophagy And Lysosomal Regulation is Key for Granulocytic Differentiation of Acute Myeloid Leukemia Cells *Magali HUMBERT,* University of Bern, Switzerland
16:35 - 16:50 - Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells *Elias EL-HABR,* Institut de Biologie Paris-Seine (IBPS), France
16:50 - 17:30 - Roles of the p53 pathway in metabolism: implications in aging, tissue homeostasis and carcinogenesis *Laurent LE CAM,* Institut de Recherche en Cancérologie de Montpellier (IRCM), France

19:30 - 22:00 Medical Session (french only)

Organisation des territoires et recensement des structures Loi santé et organisation territoriale Etat des lieux des dispositifs de coordination ville hôpital en Occitanie Retours d’expériences de coordination ville hôpital en cancérologie Comment le réseau peut accompagner les territoires pour favoriser la coordination ville hôpital pour les patients atteints de cancer ? Quels outils existent pour faciliter la coordination ville hôpital des patients atteints de cancer en Occitanie https://www.onco-occitanie.fr/extranet/evenement/reunion-coordination-villehopital-tow

Posters

Non-Canonical Functions of Hexokinase 3 During Myeloid Differentiation *Kristina SEILER,* Scripps Research, United States
Pancreatic ductal adenocarcinoma requires PI3K? activity to accelerate circulating DNA-positive metastatic disease. *Fernanda RAMOS-DELGADO,* CRCT , France
Targeting Mitochondrial Iron Metabolism Re-Sensitizes Resistant Acute Myeloid Leukemia Cells to Cytarabine *Estelle SALAND,* Inserm U1037, France
A drug-tolerant senescent-like state promotes EGFR-TKI resistance and can be targeted with Rho/AKT inhibitors *Sarah FIGAROL,* Cancer Research Center of Toulouse, France
A new role for cytidine deaminase in the control of DNA replication and genome stability in pancreatic cancer cells *Audrey LUMEAU,* CRCT-10, France
Psychological and social impact of adapted physical activity (APA), namely touch rugby, in patients followed for gynecological and breast cancer *Kelig VERGRIETE,* Centre Hospitalier Universitaire , France
PI3K? signaling controls the balance between tissue regeneration and precancer lesion formation via PHGDH expression in pancreatic inflammation. *Coralie CAYRON,* CRCT, France
Evaluating PRL2 as a new target for glioblastoma treatment *Tiffanie CHOULEUR,* INSERM U1029 - Université de Bordeaux, France
Molecular profiling of Midostaurin-resistant leukemic cells using CRISPR-Cas9 screening *Solène FERNANDEZ,* U1035 BMGIC- Université de Bordeaux, France
RIP140 participates in the transcriptional interplay between p53 and HIF-2alpha to regulate glucose metabolism in cancer cells *Catherine TEYSSIER,* Institut de Recherche en Cancérologie de Montpellier, France
Microtubule associated proteins as predictive biomarkers of taxane-based chemotherapy in high-grade serous ovarian cancer *Hadia MOINDJIE,* Institut Gustave Roussy, France
Cancer cells replication program flexibility in response to replication stress *Lilas COURTOT,* CRCT INSERM 1037, France
Long Noncoding RNAs in NPM1-mutated cytogenetically normal acute myeloid leukemia: clinical relevance and functional characterization *Morgane GOURVEST,* Centre de Recherches en Cancérologie de Toulouse - CRCT, France
Ceramide metabolism alterations in TNF-induced resistance to immune checkpoint blockers in melanoma *Carine DUFAU,* CRCT Inserm 1037, France
A new role of CEBPA in Acute Myeloid Leukemia : from differentiation to lipid and mitochondrial metabolism *Marie SABATIER,* CRCT - Inserm UMR1037, France
Tumor adaptation of oncolytic virus to overcome pancreatic cancer resistance to treatment *Pierre CORDELIER,* INSERM U1037 équipe 10, France
Towards precision Medicine: How bladder PDX models can support therapeutic decisions *Yolande MISSERI,* Urosphere, France
The histone variant macroH2A1.1 inhibits cellular migration by activating paused gene transcription in triple negative breast cancer cells. *Ludmila RECOULES,* CBI, France
LOSS OF WSX-1 EXPRESSION THROUGH MIR-324-5P OVEREXPRESSION IS AN INDEPENDENT RISK FACTOR FOR HEPATOCELLULAR CARCINOMA RECCURENCE *Camilia MACHOU,* University of Paris Est / INSERM U955, France
The POLE cohort: Multicentric prospective cohort of tumors with somatic mutation of the DNA polymerase PolE, from bed side to bench ! *Nadim FARES,* Cancer Research Center of Toulouse - CRCT, France
Feasibility of circulating tumour DNA quantification in early breast cancer *Hadrien Reboul,* Caldas lab - Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
Integrated analysis of H2A.Z isoforms function reveals a complex interplay in gene regulation *Assala LAMAA,* CBI Toulouse, CNRS, France
Free-5S particles as new anti-cancer therapeutic target *Simon LEBARON,* CBI-INSERM, France
NELF-mediated RNA polymerase II pausing protects genes from DSBs by facilitating the loading of Set2/Hypb H3K36 methyltransferase *David DEPIERRE,* CBI-LBME, France
Autophagy, a new potential therapeutic target in JAK2V617F positive Myeloproliferative Neoplasms *Charly COURDY,* Centre de Recherches en Cancérologie de Toulouse (CRCT), France
Polymorphism of Heat Shock Protein 70 (HSP70-2) and bladder cancer in an Algerian population *Meriem BELHOUT ZEBIRI,* University of Sciences and Technology Houari Boumediene, Algeria
First-in-class imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells *Lorraine QUILLIEN,* Cancer Research Centre of Toulouse (CRCT), UMR INSERM 1037, Toulouse, France, France
Selective RhoC-dependent killing of cancer cells with mesenchymal phenotype: a new determinant for parvovirus minute virus of mice oncolytic activity in PDAC *Pierre CORDELIER,* Cancer Research Center of Toulouse (CRCT), UMR INSERM U1037 Team 10, Toulouse, France, France
Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1 *Céline COLACIOS,* CRCT, France
Mechanical parameter assessment of pancreatic cancer with Magnetic Resonance Elastography *Pauline M. LEFEBVRE,* CRCT UMR1037 INSERM-UNIVERSITE TOULOUSE 3 - ERL5294 CNRS , France
Role of CD36 in the response to chemotherapy in Acute Myeloid Leukemia *Thomas FARGE,* INSERM, France
KDM5 histone-demethylases contribute to replication stress response and tolerance *Marie VANDROMME,* CBI/LBCMCP UMR5088 CNRS/UPS, France
DeltaNp63 expression in HPV-related head and neck cancers impacts patients' prognosis, cancer cell aggressiveness and the intra-tumoral immune landscape *Alain JUNG,* Centre de lutte contre le cancer Paul Strauss, France
A catalytic-independent function of the human DNA polymerase Kappa controls the pool of the checkpoint kinase Chk1 *Marie-Jeanne PILLAIRE,* INSERM - CRCT, France
The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities *Melissa ALAME,* Institut de Recherche en Cancérologie de Montpellier, France
Conception, Preclinical and clinical validations of "Imdendrim", a new anti-cancer agent derived from the nanotechnology *Hafid BELHADJ-TAHAR,* AFPREMED, France
MET exon 14 skipping mutations in lung cancer: Screening, functional and clinical impact *David TULASNE,* CNRS UMR8161, France
The T cell bispecific antibody CD20-TCB shows high in vitro activity against in vivo ibrutinib-treated primary CLL samples *Anne QUILLET-MARY,* CRCT, France
Bifunctional ligand design for modulating mutant P53 aggregation in cancer *Christian GAIDDON,* INSERM U1113, France
Extracellular matrix gene expression and cytotoxic T lymphocyte infiltration in the tumor microenvironment in non-small cell lung cancer *Sara MILOSEVIC,* Advanced Cell Diagnostics, a Bio-Techne Brand, France
JMJD6 participates in the maintenance of ribosomal DNA integrity in response to DNA damage *Yvan CANITROT,* CBI LBCMCP CNRS, France
Innovative technical platform in radiochemistry and radiopharmacy (Pi-R2) *Manon PEREZ,* Toulouse Neuro Imaging Center (ToNIC) UMR1214 Inserm/UPS, France
Targeting sphingosine-metabolizing enzymes: a novel strategy to bypass immune resistance in experimental melanoma *Alexandre GHENASSIA,* INSERM UMR 1037 CRCT, France
Genetic variations of ABC transporters and CYP450 associated with Trabectedin hepatotoxicity in patients with advanced soft-tissue sarcomas: a pharmacogenetic study. *Maud MAILLARD,* Team 14 CRCT INSERM UMR1037, France
HDAC4 levels control sensibility toward cisplatin in gastric cancer via p53/p73/BIK pathway *Georg MELLITZER,* INSERM UMR_S1113, France
Modeling Cancer Initiation *Adouda ADJIRI,* University FA Setif-1 Faculty of Sciences , Algeria
Senescence as an adaptive, oncogenic mechanism *Olivier COQUERET,* Inserm U1232, ICO Paul Papin, France
CD137 receptor as a candidate for therapeutic induction of high endothelial venules in solid tumors *Lucas BLANCHARD,* Institut de Pharmacologie et de Biologie Structurale, France
Using DNA methylation to characterize cell types in the tumour microenvironment *Ting XIE,* Inserm Centre de Recherches en Cancerologie de Toulouse, France
The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression *David ESTEVE,* Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, Toulouse, France, France
Investigating pluripotency, differentiation, cancer and resistance using network representations of the genome *Vera PANCALDI,* Inserm Centre de Recherches en Cancerologie de Toulouse, France
Concomitant targeting of calcium mitochondrial homeostasis and autophagy: a new strategy to increase chemosensitivity of solid cancers. *Charlotte DUBOIS,* INSERM, France
Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth *Jean Philippe HUGNOT,* Université de Montpellier, France
Development of an TAM targeting antibody for cancer therapy *Marcin DOMAGALA,* Cancer Research Center of Toulouse, France
Microtubule-associated ATIP3 deficiency sensitizes breast tumors to paclitaxel by increasing aneuploidy *Sylvie RODRIGUES-FERREIRA,* Institut Gustave Roussy, France
The Study of Synergistic and Protective Effects of Three Different Polar Saffron Extracts and Photon Radiation on Human Colorectal Cancer Cells (Ht-29) and Normal Human *Roham SALEK,* mashhad univercity of medical scienses , Iran
Multiscale modelling of macrophage polarization in Chronic Lymphocytic Leukemia *Nina VERSTRAETE,* Cancer Research Center of Toulouse UMR 1037 Inserm - Université Toulouse III Paul Sabatier, France
Tumor growth, progression and immune escape are modulated by ATRX alterations in pleomorphic sarcomas *Lucie DARMUSEY,* CRCT, France
Detection of BRAF V600E mutation by immunohistochemistry and PCR- RFLP in Moroccan patients with Pediatric Low-Grade Gliomas *Soufiane HENNANI,* Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II - Casablanca, Morocco , Morocco
Phosphoantigenic activation of Vg9Vd2 T lymphocytes: involvement of RHOB in a lung cancer model *Chloé LAPLAGNE,* Cancer Research Center of Toulouse - CRCT , France
PRIMAGE: PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers *Thomas TROUILLARD,* Medexprim, France
A better understanding of the E3 ubiquitin ligase TRIP12 heterogeneity to better treat pancreatic cancer *Manon BRUNET,* Inserm U1037-CRCT, France

More information about Invited Speakers

PCO agency - partner of the event :

INSIGHT OUTSIDE

contact@toulouse-onco-week.org
http://www.insight-outside.fr

Project holder :

GIP IUCT
1 Av. Irène Joliot-Curie
31100 Toulouse

http://www.iuct.fr

TOW 2020 • Scientific & B2B Programme • Plan your venue • Sponsors and Supporters • Public Events • Press • Past editions

(*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.

According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE 26 Avenue Jean Kuntzmann 38330 Montbonnot-Saint-Martin / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.

© 2005 - 2020 Insight Outside